Cardax, Inc. (CDXI)
Cardax, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Honolulu, HI, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $80. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -938.0%. Its beta of -3.20 implies it has historically moved less than the broad market.
Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity. This product is primarily distributed through online sales and wholesale channels. The company is also progressing two pharmaceutical candidates: CDX-101, an astaxanthin-derived drug candidate intended to address cardiovascular inflammation and dyslipidemia, with a primary focus on severe hypertriglyceridemia; and CDX-301, a zeaxanthin-based pharmaceutical currently under development for macular degeneration. Cardax, Inc. maintains its headquarters in Honolulu, Hawaii.
Cardax, Inc. is most often compared with the following Healthcare names: